CELC
Celcuity Makes Monumental Progress in Advancing Clinical Development of Gedatolisib for HR-Positive, HER2-Negative Advanced Breast Cancer
Celcuity continues to make significant strides in advancing clinical development of its flagship therapy, gedatolisib, for patients with HR-positive, HER2-negative advanced breast cancer. The company's latest quarterly update highlights a series of impressive milestones achieved in the second quarter of 2026. According to Brian Sullivan, CEO of Celcuity,